Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1482) 1482
Publication (74) 74
Book / eBook (37) 37
Book Chapter (7) 7
Magazine Article (5) 5
Book Review (3) 3
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1168) 1168
hyperkinesis - drug therapy (944) 944
male (878) 878
child (743) 743
female (547) 547
animals (436) 436
hyperkinesis - chemically induced (353) 353
index medicus (278) 278
child, preschool (274) 274
methylphenidate - therapeutic use (261) 261
adolescent (259) 259
rats (236) 236
neurosciences (229) 229
mice (192) 192
motor activity - drug effects (184) 184
adult (173) 173
hyperkinesis - etiology (172) 172
pharmacology & pharmacy (155) 155
psychiatry (153) 153
dose-response relationship, drug (151) 151
hyperkinesis - physiopathology (148) 148
disease models, animal (132) 132
clinical trials as topic (128) 128
clinical neurology (127) 127
dextroamphetamine - therapeutic use (127) 127
hyperkinesis - diagnosis (123) 123
hyperkinesis (114) 114
hyperactivity (113) 113
middle aged (112) 112
time factors (108) 108
hyperkinesis - psychology (102) 102
hyperkinesis - therapy (101) 101
behavior, animal - drug effects (94) 94
children (91) 91
rats, sprague-dawley (90) 90
placebos (89) 89
attention deficit disorder with hyperactivity - drug therapy (86) 86
schizophrenia (80) 80
child behavior disorders - drug therapy (79) 79
aged (78) 78
infant (74) 74
dopamine (73) 73
age factors (69) 69
pediatrics (69) 69
analysis of variance (68) 68
electroencephalography (68) 68
methylphenidate - adverse effects (67) 67
attention - drug effects (66) 66
attention-deficit hyperactivity disorder (64) 64
amphetamine (62) 62
hyperkinesis - complications (62) 62
hyperkinesis - metabolism (62) 62
hyperkinesis - genetics (60) 60
brain (59) 59
dopamine - metabolism (59) 59
methylphenidate - pharmacology (59) 59
schizophrenia - drug therapy (59) 59
drug therapy (58) 58
rats, wistar (56) 56
methylphenidate - administration & dosage (54) 54
amphetamine - therapeutic use (53) 53
antipsychotic agents - therapeutic use (53) 53
psychological tests (53) 53
antipsychotic agents - pharmacology (52) 52
mice, inbred c57bl (52) 52
parkinson disease - drug therapy (50) 50
behavior (48) 48
follow-up studies (48) 48
neurology (48) 48
behavior therapy (47) 47
double-blind method (47) 47
drug interactions (46) 46
treatment outcome (46) 46
drug evaluation (45) 45
attention (44) 44
diagnosis, differential (43) 43
rat (43) 43
amphetamine - pharmacology (42) 42
brain - metabolism (42) 42
analysis (41) 41
hyperkinesis - prevention & control (41) 41
locomotor activity (41) 41
methylphenidate (40) 40
mice, knockout (40) 40
article (39) 39
attention deficit disorder with hyperactivity - diagnosis (39) 39
brain - drug effects (39) 39
central nervous system stimulants - therapeutic use (39) 39
tranquilizing agents - therapeutic use (39) 39
dextroamphetamine - adverse effects (37) 37
hyperkinesia (36) 36
pregnancy (36) 36
anticonvulsants - therapeutic use (35) 35
attention-deficit/hyperactivity disorder (35) 35
central nervous system stimulants - pharmacology (35) 35
hyperactive children (35) 35
imipramine - therapeutic use (35) 35
adhd (34) 34
rodents (34) 34
dextroamphetamine - pharmacology (33) 33
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
OISE - Stacks (22) 22
Gerstein Science - Stacks (21) 21
UTL at Downsview - May be requested (5) 5
UofT at Mississauga - Stacks (5) 5
Robarts - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
OISE - Lost (1) 1
Regis College - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1331) 1331
German (74) 74
Russian (43) 43
French (19) 19
Italian (10) 10
Spanish (10) 10
Japanese (9) 9
Polish (7) 7
Danish (4) 4
Czech (3) 3
Hebrew (3) 3
Norwegian (3) 3
Bulgarian (2) 2
Croatian (2) 2
Dutch (2) 2
Chinese (1) 1
Finnish (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature
by Chen, Jack J., PharmD, FCCP, BCPS, CGP and Ondo, William G., MD and Dashtipour, Khashayar, MD, PhD and Swope, David M., MD
Clinical Therapeutics, ISSN 0149-2918, 2012, Volume 34, Issue 7, pp. 1487 - 1504
Abstract Background Tetrabenazine (TBZ) is a monoamine storage inhibitor that was first introduced in the 1970s for the management of hyperkinetic movement... 
Internal Medicine | Medical Education | tetrabenazine | tics | dystonia | Huntington disease | tardive dyskinesia | Tics | Dystonia | Tardive dyskinesia | Tetrabenazine | PHARMACOLOGICAL MANAGEMENT | EARLY HUNTINGTONS-DISEASE | POSITRON-EMISSION-TOMOGRAPHY | THERAPY | CHOREA | VESICULAR MONOAMINE TRANSPORTER | TOURETTES-SYNDROME | NEUROLEPTIC MALIGNANT SYNDROME | PHARMACOLOGY & PHARMACY | TARDIVE-DYSKINESIA | Adrenergic Uptake Inhibitors - adverse effects | Rare Diseases - physiopathology | Chorea - physiopathology | Tic Disorders - physiopathology | Adrenergic Uptake Inhibitors - therapeutic use | Chorea - drug therapy | Humans | Rare Diseases - drug therapy | Dystonia - physiopathology | Hyperkinesis - physiopathology | Dystonia - drug therapy | Hyperkinesis - drug therapy | Animals | Movement Disorders - physiopathology | Tetrabenazine - pharmacology | Adrenergic Uptake Inhibitors - pharmacology | Tic Disorders - drug therapy | Huntington Disease - drug therapy | Tetrabenazine - adverse effects | Huntington Disease - physiopathology | Movement Disorders - drug therapy | Tetrabenazine - therapeutic use | Medical colleges | Care and treatment | Huntington's chorea | Movement disorders | Studies | Pediatrics | Dopamine | Metabolites | Text editing | Parkinsons disease | Tourette syndrome | Drug dosages | Manuscripts
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome
by Martínez-Cué, Carmen and Martínez, Paula and Rueda, Noemí and Vidal, Rebeca and García, Susana and Vidal, Verónica and Corrales, Andrea and Montero, Juan A and Pazos, Ángel and Flórez, Jesús and Gasser, Rodolfo and Thomas, Andrew W and Honer, Michael and Knoflach, Frédéric and Trejo, Jose Luis and Wettstein, Joseph G and Hernández, Maria-Clemencia
Journal of Neuroscience, ISSN 0270-6474, 02/2013, Volume 33, Issue 9, pp. 3953 - 3966
Down syndrome (DS) is associated with neurological complications, including cognitive deficits that lead to impairment in intellectual functioning. Increased... 
Protein Binding - genetics | Electric Stimulation | Cell Count | Male | GABA Modulators - therapeutic use | Learning Disorders - etiology | Hyperkinesis - drug therapy | Neurogenesis - genetics | Long-Term Potentiation - drug effects | Protein Binding - drug effects | Exploratory Behavior - drug effects | Reflex, Startle - drug effects | Imidazoles - therapeutic use | Excitatory Postsynaptic Potentials - genetics | Disease Models, Animal | Mice, Transgenic | Hippocampus - pathology | Imidazoles - pharmacology | Psychomotor Performance - drug effects | Hyperkinesis - etiology | Vesicular Inhibitory Amino Acid Transport Proteins - metabolism | Analysis of Variance | Seizures - etiology | Glutamate Decarboxylase - metabolism | Mice | Receptors, GABA-A - metabolism | Benzodiazepines - therapeutic use | Tritium - pharmacokinetics | Sensory Gating - drug effects | Reflex - genetics | Reflex - drug effects | Hippocampus - drug effects | Excitatory Postsynaptic Potentials - drug effects | Ki-67 Antigen | Reaction Time - drug effects | GABA Modulators - pharmacology | Neurons - physiology | Down Syndrome - complications | Membrane Proteins - metabolism | Neurogenesis - drug effects | Neurons - drug effects | Cues | Down Syndrome - pathology | Benzodiazepines - pharmacology | Acoustic Stimulation | Mice, Inbred C57BL | Learning Disorders - drug therapy | Long-Term Potentiation - genetics | Biophysics | Maze Learning - drug effects | Rotarod Performance Test | Animals | Carrier Proteins - metabolism | Down Syndrome - drug therapy | Cell Proliferation - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Dopamine depleters in the treatment of hyperkinetic movement disorders
by Jankovic, Joseph
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 12/2016, Volume 17, Issue 18, pp. 2461 - 2470
Introduction: Abnormal involuntary movements often improve in response to anti-dopaminergic drugs. In contrast to classic neuroleptics that block dopamine... 
vesicular monoamine transporter | hyperkinetic movements | orphan drug | Huntington disease | valbenazine | VMAT2 | tetrabenazine | Deutetrabenazine | chorea | Tourette syndrome | dopamine | tardive dyskinesia | DRUG | DYSTONIA | TOURETTE-SYNDROME | VESICULAR MONOAMINE TRANSPORTER-2 | MOTOR | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TARDIVE-DYSKINESIA | Tardive Dyskinesia - drug therapy | Receptors, Dopamine - metabolism | Humans | Tardive Dyskinesia - metabolism | Tics - metabolism | Dopamine Antagonists - therapeutic use | Treatment Outcome | Hyperkinesis - metabolism | Huntington Disease - metabolism | Hyperkinesis - drug therapy | Movement Disorders - metabolism | Animals | Antipsychotic Agents - therapeutic use | Huntington Disease - drug therapy | Tics - drug therapy | Dopamine - metabolism | Movement Disorders - drug therapy | Tetrabenazine - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Aripiprazole for autism spectrum disorders (ASD)
by Hirsch, Lauren E and Pringsheim, Tamara
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2016, Volume 2016, Issue 6, p. CD009043
Background Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified... 
EFFICACY | IRRITABILITY | HALOPERIDOL | Humans | BEHAVIOR | Irritable Mood [drug effects] | Male | OBSESSIVE-COMPULSIVE SCALE | PREVALENCE | Aripiprazole | Quinolones [therapeutic use] | PERVASIVE DEVELOPMENTAL DISORDERS | Randomized Controlled Trials as Topic | CHILDREN | MEDICINE, GENERAL & INTERNAL | Child Development Disorders, Pervasive [drug therapy] | ADOLESCENTS | Adolescent | DOUBLE-BLIND | Female | Antipsychotic Agents [therapeutic use] | Hyperkinesis [drug therapy] | Child | Piperazines [therapeutic use] | Antipsychotic Agents - therapeutic use | Aripiprazole - therapeutic use | Irritable Mood - drug effects | Child Development Disorders, Pervasive - drug therapy | Hyperkinesis - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Epileptiform activity and cognitive deficits in SNAP-25+/- mice are normalized by antiepileptic drugs
by Corradini, Irene and Donzelli, Andrea and Antonucci, Flavia and Welzl, Hans and Loos, Maarten and Martucci, Roberta and De Astis, Silvia and Pattini, Linda and Inverardi, Francesca and Wolfer, David and Caleo, Matteo and Bozzi, Yuri and Verderio, Claudia and Frassoni, Carolina and Braida, Daniela and Clerici, Mario and Lipp, Hans-Peter and Sala, Mariaelvina and Matteoli, Michela
Cerebral Cortex, ISSN 1047-3211, 2014, Volume 24, Issue 2, pp. 364 - 376
Synaptosomal-associated protein of 25 kDa (SNAP-25) is a protein that participates in the regulation of synaptic vesicle exocytosis through the formation of... 
Epilepsy | Memory | SNAP-25 | Valproate | epilepsy | ALTERED LEVELS | memory | SYNAPTOSOMAL-ASSOCIATED PROTEIN | BIPOLAR DISORDER | GATED CALCIUM-CHANNELS | NEUROSCIENCES | CELL-DEATH | HYPERACTIVITY DISORDER | MEMBRANE-FUSION | valproate | MOUSE MUTANT COLOBOMA | ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | EEG DISCHARGES | Memory Disorders - physiopathology | Male | Hyperkinesis - physiopathology | Epilepsy - physiopathology | Hyperkinesis - drug therapy | Kainic Acid | Seizures - chemically induced | Seizures - physiopathology | Hyperkinesis - pathology | Neurons - physiology | Valproic Acid - therapeutic use | Neurons - drug effects | Memory Disorders - pathology | Synaptosomal-Associated Protein 25 - genetics | Cognition Disorders - physiopathology | Brain - physiopathology | Mice, Inbred C57BL | Cognition Disorders - pathology | Ethosuximide - therapeutic use | Anticonvulsants - therapeutic use | Carbamazepine - therapeutic use | Mice, Transgenic | Cognition Disorders - drug therapy | Association Learning - physiology | Association Learning - drug effects | Nimodipine - therapeutic use | Brain - drug effects | Animals | Memory Disorders - drug therapy | Brain - pathology | Epilepsy - drug therapy | Mice | Synaptosomal-Associated Protein 25 - metabolism | Epilepsy - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity
by Ishibashi, Tadashi and Horisawa, Tomoko and Tokuda, Kumiko and Ishiyama, Takeo and Ogasa, Masaaki and Tagashira, Rie and Matsumoto, Kenji and Nishikawa, Hiroyuki and Ueda, Yoko and Toma, Satoko and Oki, Hitomi and Tanno, Norihiko and Saji, Ikutaro and Ito, Akira and Ohno, Yukihiro and Nakamura, Mitsutaka
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 07/2010, Volume 334, Issue 1, pp. 171 - 181
Lurasidone [(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione... 
ANTAGONIST SB-269970 | WATER MAZE | REVERSES MK-801-INDUCED IMPAIRMENT | RAT | MEMORY | DOUBLE-BLIND | SCHIZOPHRENIA | PHARMACOLOGY & PHARMACY | GUINEA-PIG | BINDING | SM-9018 | Cricetulus | Rats, Wistar | Antipsychotic Agents - adverse effects | Humans | Receptor, Serotonin, 5-HT1A - genetics | Male | Anxiety - drug therapy | Hyperkinesis - metabolism | Thiazoles - therapeutic use | Receptors, Serotonin - genetics | Thiazoles - adverse effects | Hyperkinesis - drug therapy | Transfection | Lurasidone Hydrochloride | Antipsychotic Agents - therapeutic use | Isoindoles - therapeutic use | Behavior, Animal - drug effects | Molecular Structure | Tremor - drug therapy | Isoindoles - pharmacology | Anxiety - metabolism | Cyclic AMP - metabolism | Dopamine - metabolism | Receptor, Serotonin, 5-HT1A - metabolism | CHO Cells | Cricetinae | Guinea Pigs | Isoindoles - adverse effects | Rats | Mice, Inbred Strains | Rats, Sprague-Dawley | Receptors, Serotonin - metabolism | Animals | Protein Binding | Ligands | Tremor - metabolism | Mice | Thiazoles - pharmacology | Antipsychotic Agents - pharmacology
Journal Article
Details down arrow
7. Full Text Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
by Kenney, Christopher and Hunter, Christine and Jankovic, Joseph
Movement Disorders, ISSN 0885-3185, 01/2007, Volume 22, Issue 2, pp. 193 - 197
We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement... 
tetrabenazine | chorea | tics | tolerability | tardive dyskinesia | Tics | Tolerability | Tardive dyskinesia | Tetrabenazine | Chorea | OPEN-LABEL | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | TOURETTES-SYNDROME | DRUGS | NEUROLEPTIC MALIGNANT SYNDROME | DOUBLE-BLIND | TARDIVE-DYSKINESIA | HUNTINGTONS-DISEASE | BRAIN | Prevalence | Dyskinesia, Drug-Induced - physiopathology | Humans | Middle Aged | Drug Tolerance - physiology | Male | Hyperkinesis - physiopathology | Time | Hyperkinesis - drug therapy | Tics - epidemiology | Myoclonus - drug therapy | Dyskinesia, Drug-Induced - drug therapy | Parkinsonian Disorders - drug therapy | Adult | Female | Anti-Dyskinesia Agents - administration & dosage | Retrospective Studies | Huntington Disease - physiopathology | Severity of Illness Index | Tetrabenazine - administration & dosage | Parkinsonian Disorders - physiopathology | Dyskinesia, Drug-Induced - epidemiology | Drug Administration Schedule | Parkinsonian Disorders - epidemiology | Huntington Disease - etiology | Myoclonus - physiopathology | Anti-Dyskinesia Agents - therapeutic use | Huntington Disease - epidemiology | Anti-Dyskinesia Agents - adverse effects | Age of Onset | Tetrabenazine - adverse effects | Hyperkinesis - epidemiology | Myoclonus - epidemiology | Tics - drug therapy | Tics - physiopathology | Tetrabenazine - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: A twelve-week follow-up study
by Homsi, Shadi and Piaggio, Tomaso and Croci, Nicole and Noble, Florence and Plotkine, Michel and Marchand-Leroux, Catherine and Jafarian-Tehrani, Mehrnaz
Journal of Neurotrauma, ISSN 0897-7151, 05/2010, Volume 27, Issue 5, pp. 911 - 921
Traumatic brain injury (TBI) causes a wide spectrum of consequences, such as microglial activation, cerebral inflammation, and focal and diffuse brain injury,... 
Minocycline | Traumatic brain injury | Locomotor hyperactivity | Diffuse axonal injury | Microglial activation | diffuse axonal injury | CEREBRAL EDEMA | traumatic brain injury | AMYLOID PRECURSOR PROTEIN | AMYOTROPHIC-LATERAL-SCLEROSIS | MODEL | locomotor hyperactivity | NEUROTOXICITY | NEUROSCIENCES | CLINICAL NEUROLOGY | EXCITATORY AMINO-ACIDS | TRAUMATIC BRAIN-INJURY | FLUID PERCUSSION INJURY | minocycline | EXPRESSION | microglial activation | AXONAL INJURY | CRITICAL CARE MEDICINE | Microglia - metabolism | Head Injuries, Closed - pathology | Follow-Up Studies | Microglia - drug effects | Brain Injuries - drug therapy | Minocycline - pharmacology | Male | Treatment Outcome | Hyperkinesis - drug therapy | Gliosis - pathology | Hyperkinesis - prevention & control | Animals | Hyperkinesis - pathology | Neuroprotective Agents - pharmacology | Time Factors | Microglia - pathology | Gliosis - drug therapy | Mice | Brain Injuries - pathology | Head Injuries, Closed - drug therapy | Disease Models, Animal | Animal experimentation | Brain | Usage | Prognosis | Cell death | Physiological aspects | Research | Injuries | Drug therapy | Brain damage | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways
by Papaleo, F and Yang, F and Garcia, S and Chen, J and Lu, B and Crawley, J.N and Weinberger, D.R
Molecular Psychiatry, ISSN 1359-4184, 01/2012, Volume 17, Issue 1, pp. 85 - 98
Dysbindin-1 regulates D2-receptor trafficking and is implicated in schizophrenia and related cognitive abnormalities, but whether this molecular effect... 
schizophrenia | genes | working memory | dopamine | mice | prefrontal cortex | PREPULSE INHIBITION | 6P22.3 GENE | PSYCHIATRY | BIOCHEMISTRY & MOLECULAR BIOLOGY | FUNCTIONAL CONNECTIVITY | HIPPOCAMPAL-FORMATION | NEUROSCIENCES | GENETIC-VARIATION | PYRAMIDAL NEURONS | D2 RECEPTOR | MESSENGER-RNA | SUSCEPTIBILITY GENE | WORKING-MEMORY | Sensory Gating - drug effects | Gene Expression Regulation, Enzymologic - drug effects | Hyperkinesis - genetics | Action Potentials - genetics | Prefrontal Cortex - physiopathology | Motor Activity - drug effects | Schizophrenia - complications | Memory, Short-Term - physiology | Schizophrenia - pathology | Receptors, Dopamine D2 - metabolism | Hyperkinesis - drug therapy | Prefrontal Cortex - pathology | Prefrontal Cortex - drug effects | Dopamine Agents - pharmacology | Reaction Time - drug effects | Sensory Gating - genetics | Mice, Inbred DBA | Pyramidal Cells - drug effects | Action Potentials - drug effects | Dopamine - metabolism | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism | Disease Models, Animal | Memory, Short-Term - drug effects | Amphetamine - adverse effects | Reaction Time - genetics | Maze Learning - drug effects | Hyperkinesis - etiology | Mice, Knockout | Dystrophin-Associated Proteins | Carrier Proteins - genetics | Motor Activity - genetics | Animals | Memory Disorders - drug therapy | Memory Disorders - etiology | Gene Expression Regulation, Enzymologic - genetics | Mice | Dysbindin | Stress, Psychological - physiopathology | Genetic aspects | Prefrontal cortex | Research | Binding proteins | Properties | Dopaminergic mechanisms | Genetic regulation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Drugs and the special child
by Cohen, Michael Jay
1979, ISBN 9780470992784, viii, 258
Pediatric psychoparmacology | Hyperactive children | Problem children | Child psychotherapy
Book
Details down arrow
11. Full Text Formulation of orodispersible films for paediatric therapy: investigation of feasibility and stability for tetrabenazine as drug model
by Senta‐Loys, Zoé and Bourgeois, Sandrine and Pailler‐Mattei, Cyril and Agusti, Géraldine and Briançon, Stéphanie and Fessi, Hatem
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 05/2017, Volume 69, Issue 5, pp. 582 - 592
Objectives Orodispersible films (ODF) were formulated to facilitate tetrabenazine (TBZ) administration to paediatric population for the treatment of... 
tetrabenazine | orodispersible film | PVP | HPMC | paediatric medicine | CRYSTALLIZATION | MUCOADHESIVE | POLY(VINYLPYRROLIDONE) | NANOPARTICLES | SOLID DISPERSIONS | HYPERKINETIC MOVEMENT-DISORDERS | DISSOLVING FILMS | PHARMACOLOGY & PHARMACY | Tetrabenazine - administration & dosage | Chemistry, Pharmaceutical - methods | Administration, Oral | Solvents - chemistry | Drug Stability | Humans | Solubility | Oral Mucosal Absorption | Administration, Buccal | Drug Liberation - drug effects | Hyperkinesis - drug therapy | Saliva - metabolism | Polymers - chemistry | Tetrabenazine - chemistry | Pediatrics | Polysaccharides | Analysis | Investigations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
by Scahill, Lawrence and McCracken, James T and King, Bryan H and Rockhill, Carol and Shah, Bhavik and Politte, Laura and Sanders, Roy and Minjarez, Mendy and Cowen, Jennifer and Mullett, Jennifer and Page, Chris and Ward, Denise and Deng, Yanhong and Loo, Sandra and Dziura, James and McDougle, Christopher J and Res Units Pediat Psychopharmacolog and Research Units on Pediatric Psychopharmacology Autism Network
American Journal of Psychiatry, ISSN 0002-953X, 12/2015, Volume 172, Issue 12, pp. 1197 - 1206
Objective:Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is... 
ADHD | ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | PLACEBO | CLINICAL-TRIAL | ABERRANT BEHAVIOR CHECKLIST | PSYCHIATRY | ADOLESCENTS | YOUNG-PEOPLE | DOUBLE-BLIND | SYMPTOMS | PERVASIVE DEVELOPMENTAL DISORDERS | Hyperkinesis - complications | Double-Blind Method | Humans | Autism Spectrum Disorder - complications | Child, Preschool | Guanfacine - administration & dosage | Guanfacine - therapeutic use | Male | Memory, Short-Term - drug effects | Treatment Outcome | Psychomotor Performance - drug effects | Autism Spectrum Disorder - psychology | Delayed-Action Preparations - administration & dosage | Hyperkinesis - drug therapy | Neuropsychological Tests | Adrenergic alpha-2 Receptor Agonists - administration & dosage | Adrenergic alpha-2 Receptor Agonists - therapeutic use | Hyperkinesis - psychology | Adolescent | Delayed-Action Preparations - therapeutic use | Female | Autism Spectrum Disorder - drug therapy | Child | Autism | Attention-deficit hyperactivity disorder | Guanfacine | Dosage and administration | Drug therapy | Autistic children
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights